Mutation Status and Immunohistochemical Correlation of Mutations in Gastrointestinal Stromal Tumors

Overview

Journal Balkan J Med Genet

Publisher Sciendo

Specialty Genetics

Date 2021 Aug 27

PMID 34447661

Authors

H Ozkayalar

M C Ergoren

G Tuncel

S Kurt

E Cevik

S Ozemri Sag

B Yilmaz Ozguven

F Kabukcuoglu

G Mocan

S G Temel

Affiliations

Soon will be listed here.

Abstract

Being one of the leading causes of cancer deaths worldwide and their resistance to conventional treatment methods, made gastrointestinal stromal tumors (GISTs) one of the hot topics in medical research areas in the past decade. To investigate molecular alterations underlying the tumor is of great importance to be able to develop new, targeted treatment options. In this study, GIST samples obtained from 40 Turkish patients were analyzed for actionable epidermal growth factor receptor () mutations that are related to treatment regimes in non small cell lung cancer (NSCLC) to understand whether expression is altered in GISTs. Established alterations in can make the use of tyrosine kinase inhibitors possible, which are currently used in cancer therapy, especially in NSCLC. Our results indicated that mutations are rare in GISTs. Further research is needed to sequence whole coding regions of the gene to investigate new actionable mutations in in an increased sample size.

References

Apicella M, Corso S, Giordano S . Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget. 2017; 8(34):57654-57669. PMC: 5593674. DOI: 10.18632/oncotarget.14825. View

Heinrich M, Corless C, Demetri G, Blanke C, von Mehren M, Joensuu H . Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23):4342-9. DOI: 10.1200/JCO.2003.04.190. View

Miettinen M, Lasota J . Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23(2):70-83. DOI: 10.1053/j.semdp.2006.09.001. View

Pisani P, Parkin D, Bray F, Ferlay J . Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999; 83(1):18-29. DOI: 10.1002/(sici)1097-0215(19990924)83:1<18::aid-ijc5>3.0.co;2-m. View

Voldborg B, Damstrup L, Spang-Thomsen M, Poulsen H . Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 1998; 8(12):1197-206. DOI: 10.1023/a:1008209720526. View

Huss S, Kunstlinger H, Wardelmann E, Kleine M, Binot E, Merkelbach-Bruse S . A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). Mod Pathol. 2013; 26(7):1004-12. PMC: 3701292. DOI: 10.1038/modpathol.2013.47. View

Duffy M, Lamerz R, Haglund C, Nicolini A, Kalousova M, Holubec L . Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2013; 134(11):2513-22. PMC: 4217376. DOI: 10.1002/ijc.28384. View

Lv M, Wu C, Zheng Y, Zhao N . Incidence and survival analysis of gastrointestinal stromal tumors in shanghai: a population-based study from 2001 to 2010. Gastroenterol Res Pract. 2014; 2014:834136. PMC: 4017880. DOI: 10.1155/2014/834136. View

Ergin K, Gursoy E, Basimoglu Koca Y, Basaloglu H, Seyrek K . Immunohistochemical detection of insulin-like growth factor-I, transforming growth factor-beta2, basic fibroblast growth factor and epidermal growth factor-receptor expression in developing rat ovary. Cytokine. 2008; 43(2):209-14. DOI: 10.1016/j.cyto.2008.05.013. View

10.

Moutinho C, Mateus A, Milanezi F, Carneiro F, Seruca R, Suriano G . Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer. 2008; 8:10. PMC: 2244615. DOI: 10.1186/1471-2407-8-10. View

11.

Rubin B, Heinrich M, Corless C . Gastrointestinal stromal tumour. Lancet. 2007; 369(9574):1731-41. DOI: 10.1016/S0140-6736(07)60780-6. View

12.

Hynes N, Lane H . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-54. DOI: 10.1038/nrc1609. View

13.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

14.

Lux M, Rubin B, Biase T, Chen C, Maclure T, Demetri G . KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000; 156(3):791-5. PMC: 1876850. DOI: 10.1016/S0002-9440(10)64946-2. View

15.

Shi S, Wu N, He Y, Wei X, Xia Q, Wang X . EGFR gene mutation in gastrointestinal stromal tumours. Histopathology. 2017; 71(4):553-561. DOI: 10.1111/his.13251. View

16.

Heinrich M, Corless C, Duensing A, McGreevey L, Chen C, Joseph N . PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299(5607):708-10. DOI: 10.1126/science.1079666. View

17.

Yamaoka T, Ohba M, Ohmori T . Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. Int J Mol Sci. 2017; 18(11). PMC: 5713388. DOI: 10.3390/ijms18112420. View

18.

Edris B, Espinosa I, Muhlenberg T, Mikels A, Lee C, Steigen S . ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol. 2012; 227(2):223-33. PMC: 3992120. DOI: 10.1002/path.3986. View

19.

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

20.

Cohen R . Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2003; 2(4):246-51. DOI: 10.3816/CCC.2003.n.006. View